Monday, 11 December 2017

Zydus receives final approval for Mycophenolate Mofetil Injection & Donepezil Hydrochloride Tablets

06 September 2017 | News

Both the drugs will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad

Source: Pixabay

Source: Pixabay

Zydus Cadila has received the final approval from the USFDA to market Mycophenolate Mofetil for Injection USP, 500 mg/vial indicated for use in combination with other drugs i.e., cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants.

It has also received an approval to market Donepezil Hydrochloride Tablets, in the strength of 23 mg. The drug is indicated for the treatment of dementia of the Alzheimer’s disease.

Both the drugs will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Is there a disparity in the health spending by the government?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls